Part 4: Consequences of Improper Data Collection
In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara…
CertaraOctober 31, 2024
Part 3: Ensuring Proper Data Collection
In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara…
CertaraOctober 31, 2024
Part 2: Regulatory Challenges With Data Collection
In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara…
CertaraOctober 31, 2024
Part 1: Complexities in Data Collection
In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara…
CertaraOctober 31, 2024
Mathematical Models can Assist in Broadening use of Immuno-oncology Drugs to Treat Autoimmunity
October 31, 2024 The level of immune activation is enormously influential for the progression of…
CertaraOctober 31, 2024
Mathematical Modeling and the Monkey King: Use of Modeling for More Efficient NHP Study Design
Background Monkeys and humans share a strong bond, reflected not only in a shared genetic…
CertaraOctober 30, 2024
How Generative AI is Unlocking Insights to Expand Drug Development with Dr. Chris Bouton
From accelerating therapeutic innovation to breaking down data silos, this episode dives into how AI…
CertaraOctober 30, 2024
Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women
The article titled "Using PBPK modeling to supplement clinical data and support the safe and…
CertaraOctober 30, 2024
The Complete Guide to CDISC Standards Management
Learn how to easily manage and validate against CDISC data standards our complete guide to…
CertaraOctober 30, 2024
Certara Announces New Head of Clinical Pharmacology & Translational Medical Group
RADNOR, PA – October 30, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraOctober 30, 2024
